2025 United States Autism Spectrum Disorder Treatment Revenue Opportunities Report
Description
The 2025 United States Autism Spectrum Disorder Treatment Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autism Spectrum Disorder Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in Autism Spectrum Disorder (ASD) treatment in the United States include ABA Centers of America, CentralReach, Eli Lilly & Company, and Pfizer Inc. ABA Centers of America has rapidly expanded, operating in 40 cities across 10 states, providing care in-clinic, in-home, and in the community, with revenue reaching nearly $197 million in 2023. CentralReach, a leader in autism and intellectual and developmental disabilities (IDD) care software, was acquired by Roper Technologies for $1.85 billion and serves around 200,000 daily users, underscoring its key role in technology-driven ABA therapy services.
Eli Lilly & Company and Pfizer Inc. are major pharmaceutical firms involved in developing medications targeting neurological and behavioral symptoms associated with ASD. Eli Lilly focuses on neurological issues and has broad healthcare product distribution across North America and globally. Pfizer provides pharmaceuticals addressing various health conditions, including those related to immunological and neurological disorders, with extensive manufacturing and distribution networks in the U.S. and worldwide. These companies contribute to ASD treatment through pharmacological interventions alongside the growing market for behavioral and communication therapies led by firms like ABA Centers of America and CentralReach.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autism Spectrum Disorder Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in Autism Spectrum Disorder (ASD) treatment in the United States include ABA Centers of America, CentralReach, Eli Lilly & Company, and Pfizer Inc. ABA Centers of America has rapidly expanded, operating in 40 cities across 10 states, providing care in-clinic, in-home, and in the community, with revenue reaching nearly $197 million in 2023. CentralReach, a leader in autism and intellectual and developmental disabilities (IDD) care software, was acquired by Roper Technologies for $1.85 billion and serves around 200,000 daily users, underscoring its key role in technology-driven ABA therapy services.
Eli Lilly & Company and Pfizer Inc. are major pharmaceutical firms involved in developing medications targeting neurological and behavioral symptoms associated with ASD. Eli Lilly focuses on neurological issues and has broad healthcare product distribution across North America and globally. Pfizer provides pharmaceuticals addressing various health conditions, including those related to immunological and neurological disorders, with extensive manufacturing and distribution networks in the U.S. and worldwide. These companies contribute to ASD treatment through pharmacological interventions alongside the growing market for behavioral and communication therapies led by firms like ABA Centers of America and CentralReach.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
